Navigation Links
RainDance Technologies Appoints McNary President and CEO
Date:11/28/2007

GUILFORD, Conn., Nov. 28 /PRNewswire/ -- RainDance Technologies, Inc., a developer of NanoReactor droplet-based microfluidic technology, today announced the appointment of Christopher McNary as President and Chief Executive Officer. McNary will join Jonathan Rothberg, Chairman of the Board, in driving RainDance Technologies' vision and the upcoming commercial launch of its Professional Laboratory System in the Life Sciences and other related markets.

"Mr. McNary joins an outstanding leadership team that includes a distinguished Scientific Advisory Board with three Nobel Prize recipients and a Board of Directors with the former Presidents of Applied Biosystems and Affymetrix, plus an experienced Partner from Mohr Davidow Ventures," said Rothberg. "He will assist us in attracting additional talent to develop first-rate manufacturing and customer support capabilities and to commercially launch our exciting new products and applications."

The RainDance Professional Laboratory System combines microdroplets and microfluidics to enable a host of nanoscale cell-based and molecular assays. Samples (cells, beads, DNA templates, chemical compounds) and reactants are encapsulated in individual micron-sized droplets on assay-specific NanoReactor chips. With each droplet being the equivalent of a well in a microtiter plate, the Professional Laboratory System can process and analyze 10,000 samples per second with unparalleled accuracy. The precise manipulation of minute amounts of fluids within NanoReactor droplets will benefit a variety of industrial and research applications, including DNA sequencing preparation, enzyme engineering, functional cell sorting, multiplex PCR, SNP detection, gene expression, and RNAi functional assays.

"Our Professional Laboratory System is game-changing technology that has attracted a tremendous level of market interest," said Darren Link, Senior Vice President of Research and Development and RainDance Technologies founder. "Mr. McNary's depth of expertise and proven leadership in the commercialization of life science tools will be instrumental in guiding our company's growth. I look forward to working with him and our visionary Board of Directors to transform the future of laboratory practices," he said.

Mr. McNary has more than 25 years of experience in Life Sciences and Diagnostic markets with 14 years in senior management positions. He joins RainDance from Thermo Fisher Scientific where he was Vice President and General Manager. He also has served as President and CEO of early-stage start-up companies and held executive management positions at Chiron Diagnostics and Tecan.

"RainDance has built an impressive management team supported by a Scientific Advisory and Board of Directors with the proven experience in commercializing innovative technology platforms such as the Professional Laboratory System," said McNary. "This team and platform are well positioned to realize the full benefits of microfluidics in a variety of markets and applications."

About RainDance Technologies, Inc.

RainDance Technologies, Inc. is a nanotechnology company devoted to developing and commercializing the Professional Laboratory System, a platform for droplet-based microfluidics. The Professional Laboratory System is an integrated fluid handling system that provides precise manipulation of minute amounts of fluids for a variety of industrial and research applications within genomic, drug discovery, industrial enzyme development, and molecular diagnostic markets. At the core of the system's power are assay-specific NanoReactor chips composed of fluid handling modules that encapsulate samples and reactants in individual micron-sized droplets. Founded in 2004 by scientists from Harvard University, the Medical Research Centre in Cambridge, and the ESPCI in Paris, RainDance Technologies designed the Professional Laboratory System to be the chemical equivalent of a personal computer. As a computer manipulates bits of information, the system's NanoReactor technology enables the programmable handling of cells and fluid samples for innovative assay and screening applications. The promise of this technology has attracted an outstanding Scientific Advisory Board, including three Nobel Prize winners (Jean-Marie Lehn, Sir Aaron Klug, and Dr. Richard Roberts) and Sir Gregory Winter. For more information, please visit http://www.raindancetechnologies.com.


'/>"/>
SOURCE RainDance Technologies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
2. Healthcare Technologies Calls for a Shareholders Meeting to Approve the Nexgen Biofuels Transaction
3. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
4. BioMaxx Systems Inc. Signs Engagement Letter With Alcofuel Technologies for Provision of an Ethanol Micro-Refinery
5. Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Reviews Prestigious TR35 List of Top Young Innovators
6. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
7. Pathway Medical Technologies Adds Joe Rafferty as VP, Sales, and Moves To Larger Facility to Accommodate Rapid Growth
8. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
9. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
10. Microchip Biotechnologies, Inc. Secures Exclusive License to Use New University of Alberta Technology for Developing Microfluidic Devices
11. DNA Sequencing Equipment Market to Fragment and Grow as Competition, New Technologies Develop
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2016)... TORONTO , Nov. 30, 2016 /PRNewswire/ - Portage ... Canadian Securities Exchange: PBT.U), is excited to announce ... company focused on developing preclinical ophthalmology assets through ... a potent anti-inflammatory created by Portage Pharmaceuticals Limited ... patients with ocular surface and anterior segment diseases. ...
(Date:11/30/2016)... Nov. 30, 2016  The Allen Institute for ... the first publicly available collection of gene edited, ... target key cellular structures with unprecedented clarity. Distributed ... powerful tools are a crucial first step toward ... understand what makes human cells healthy and what ...
(Date:11/30/2016)... CHICAGO , Nov. 30, 2016  Tempus, ... customized cancer care, and Penn,s Abramson Cancer Center ... have a positive response to immunotherapy treatment based ... As part of a research collaboration, ... pancreatic and melanoma cancer patient data to Penn. ...
(Date:11/30/2016)... BILLERICA, Massachusetts , 30. November 2016 ... und Technologieunternehmen, hat heute die Unterzeichnung einer ... gegeben. Diesen zufolge wird Evotec AG Screeningleistungen ... und shRNA-Bibliotheken bereitstellen. Der Zugriff auf diese ... Bereich Screening eröffnet einen schnelleren Weg zur ...
Breaking Biology Technology:
(Date:11/15/2016)... 2016  Synthetic Biologics, Inc. (NYSE MKT: SYN), ... the gut microbiome, today announced the pricing of ... its common stock and warrants to purchase 50,000,000 ... to the public of $1.00 per share and ... the offering, excluding the proceeds, if any from ...
(Date:6/27/2016)... Research and Markets has announced the addition of the ... offering. The report forecasts the ... at a CAGR of 12.28% during the period 2016-2020. ... analysis with inputs from industry experts. The report covers the market ... also includes a discussion of the key vendors operating in this ...
(Date:6/21/2016)... 2016 NuData Security announced today that Randy ... principal product architect and that Jon Cunningham ... development. Both will report directly to Christopher ... reflect NuData,s strategic growth in its product and ... demand and customer focus values. ...
Breaking Biology News(10 mins):